Literature DB >> 25645812

Piperine prevents cholesterol gallstones formation in mice.

Xiu-Yun Song1, Shuang Xu2, Jin-Feng Hu1, Jia Tang1, Shi-Feng Chu1, Hang Liu1, Ning Han1, Jing-Wei Li2, Dong-Ming Zhang1, Yue-Ting Li3, Nai-Hong Chen4.   

Abstract

Biliary cholesterol may contribute to the formation of cholesterol gallstones, and regulation of these levels could be a useful therapeutic strategy for gallstones disease. Piperine (PA) is a potential cholesterol lowering agent. In this study, we assessed the effect and mechanism of PA in preventing cholesterol gallstones formation induced by feeding lithogenic diet containing high cholesterol levels to mice. C57BL/6 inbred mice were fed lithogenic or chow diets for 10 weeks, with or without PA (15, 30 and 60 mg/kg) or ursodeoxycholic acid (UDCA, 60 mg/kg) administration. Cholesterol, phospholipids and crystals in bile, the lipid in serum, pathological changes and proteins expression in liver were analyzed. The results showed that PA could decrease the cholesterol potency and crystals in bile, reduce total cholesterol (TC), triglycerides (TG) and increase high-density lipoprotein/low-density lipoprotein (HDL/LDL) levels in serum. Furthermore, PA treatment reduced liver lipid peroxidation and protected hepatobiliary cells from liver injury by decreasing malondialdehyde (MDA) and increasing superoxide dismutase (SOD). In addition, PA inhibited the expression of ATP-binding cassette transporters G5/8 (ABCG5/8) and liver X receptor (LXR) in liver, and reduced cholesterol transport from the hepatocytes to the gallbladder. It may be the mechanism of PA in preventing cholesterol gallstones formation. PA as a potential drug for prevention cholesterol gallstones merits further investigation.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ATP-binding cassette transporters; Biliary cholesterol; Cholesterol gallstones; Liver X receptor; Piperine

Mesh:

Substances:

Year:  2015        PMID: 25645812     DOI: 10.1016/j.ejphar.2015.01.038

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

Review 1.  Traditional Chinese medicine for lipid metabolism disorders.

Authors:  Yiping Li; Xiaolong Wang; Zhijie Shen
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

2.  Anticonvulsant effect of piperine ameliorates memory impairment, inflammation and oxidative stress in a rat model of pilocarpine-induced epilepsy.

Authors:  Ke Mao; Ding Lei; Heng Zhang; Chao You
Journal:  Exp Ther Med       Date:  2016-12-27       Impact factor: 2.447

3.  Anti-inflammatory effect of different curcumin preparations on adjuvant-induced arthritis in rats.

Authors:  Ieva Rinkunaite; Egidijus Simoliunas; Milda Alksne; Dominyka Dapkute; Virginija Bukelskiene
Journal:  BMC Complement Med Ther       Date:  2021-01-21

4.  Prevention of Cholesterol Gallstone Formation by Lactobacillus acidophilus ATCC 43121 and Lactobacillus fermentum MF27 in Lithogenic Diet-Induced Mice.

Authors:  Ju Kyoung Oh; You Ra Kim; Boin Lee; Young Min Choi; Sae Hun Kim
Journal:  Food Sci Anim Resour       Date:  2021-03-01

5.  Prevention of gallstones by Lidan Granule: Insight into underlying mechanisms using a guinea pig model.

Authors:  Xiao Wu; Xiaoqiang Liang; Yijie DU; Yan Zhang; Meng Yang; Weiyi Gong; Baojun Liu; Jingcheng Dong; Ningxia Zhang; Hongying Zhang
Journal:  Biomed Rep       Date:  2016-05-06

Review 6.  Recent advances in understanding and managing cholesterol gallstones.

Authors:  Agostino Di Ciaula; Piero Portincasa
Journal:  F1000Res       Date:  2018-09-24

7.  Pioglitazone prevents cholesterol gallstone formation through the regulation of cholesterol homeostasis in guinea pigs with a lithogenic diet.

Authors:  Tao Han; Yangge Lv; Shijia Wang; Tao Hu; Hao Hong; Zan Fu
Journal:  Lipids Health Dis       Date:  2019-12-11       Impact factor: 3.876

Review 8.  Natural Products Targeting Liver X Receptors or Farnesoid X Receptor.

Authors:  Jianglian She; Tanwei Gu; Xiaoyan Pang; Yonghong Liu; Lan Tang; Xuefeng Zhou
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.